PBAC's latest decision on Bimekizumab: Recommended (2025). Considered for Treatment of severe chronic plaque psoriasis in adult patients as a single 320 mg injection administered subcutaneously at weeks 0, 4, 8, 12, 16 and every 8 weeks thereafter.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
7
first 2022
Submissions
7
2022 → 2025
Eligible population
Adults with severe chronic plaque psoriasis requiring a 320 mg dose, currently treated with bimekizumab 160 mg in 1 mL pre-filled pen (two injections).
Therapy area
Dermatology
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Surrogate
Pivotal trial size
71 patients
Key trials
UP0119
Comparator
bimekizumab 160 mg in 1 mL single use pre-filled pen (two injections)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
Submission history
Mar 2022: Recommended with restriction · Authority Required
Mar 2023: Recommended with restriction · Authority Required
Mar 2024: Recommended with restriction · Authority Required
Mar 2024: Recommended with restriction · Authority Required
Mar 2024: Recommended with restriction · Authority Required
May 2025: Recommended with restriction · Authority Required